Skip to main content

Novel Second Generation Anti-HIV shRNA Expressing vif and Decoy TAR Arrest the Virus-breakthrough Phenomenon Associated With siRNA-escape Variants

We describe a novel chimera RNA expressing vif short-hairpin RNA (shRNA) and decoy trans-activation response region (TAR) RNA from a human U6 Pol II promoter, which enhanced the inhibition of human immunodeficiency virus (HIV) vif small-interfering RNA (siRNA) and arrested virus breakthrough by siRNA-generated escape variants in long-term culture assays. Our strategy was based on a second-generation anti-HIV-1 shRNA vector system, in which HIV-1 vif shRNA was fused to a decoy TAR RNA by a linker UU cleavage site to generate vif shRNA-decoy TAR RNA. Upon expression, the RNA molecule was cleaved and separated into vif siRNA and decoy TAR RNA. The synergistic effect of these molecules enhanced the inhibition of HIV-1 replication in a long-term culture assay and prevented virus breakthrough associated with siRNA-mediated escape variants. Combining shRNA with decoy TAR RNA as second-generation anti-HIV shRNA may provide practical basis for applying siRNA-based gene therapy to the treatment of HIV/AIDS.

Author information

Affiliations

Authors

Corresponding author

Correspondence to H Takaku.

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/2.0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Barnor, J., Miyano-Kurosaki, N., Abumi, Y. et al. Novel Second Generation Anti-HIV shRNA Expressing vif and Decoy TAR Arrest the Virus-breakthrough Phenomenon Associated With siRNA-escape Variants. Retrovirology 2, P36 (2005). https://doi.org/10.1186/1742-4690-2-S1-P36

Download citation

Keywords

  • Human Immunodeficiency Virus
  • Synergistic Effect
  • Gene Therapy
  • Cleavage Site
  • Response Region